Heart disease, diabetes, high blood pressure, high cholesterol, lung disease — these chronic conditions don't get cured. They just get "managed" with a pill you take every single day, without a break. That means one patient is a customer who comes back to buy, every month, for the next ten or twenty years. And as society ages, the patient base grows on its own, no matter what the economy does. This is the story of the "chronic-disease drug franchise" — durable, predictable revenue, right up until the day the patent expires and the whole thing vanishes.
Teva Study Finds Providers Prioritize Drowsiness Risk When Choosing Tardive Dyskinesia Treatment for Older Patients
Teva Pharmaceuticals announced new data showing that healthcare providers prioritize drowsiness risk, the duration of available long-term response data and drug-drug interaction profile when selecting a VMAT2 inhibitor for tardive dyskinesia in patients aged 55 and older. In a discrete choice experiment, 489 healthcare providers ranked somnolence risk, accounting for 26.8% to 36.2% of decision-making weight, and short-term symptom improvement, at 24.4% to 29.5%, as their top priorities, followed by dose formulation at 16.7% to 20.2% and drug-drug interaction risk at 14.4% to 17.3%. Applying those preferences across four patient profiles, AUSTEDO, also known as deutetrabenazine, had the highest predicted choice probability, driven mainly by somnolence risk, duration of long-term response data and drug-drug interaction. The findings were presented at Psych Congress, held September 15 to 19, 2026, in New Orleans. A separate interim analysis from the IMPACT-TD Registry found that among patients with probable tardive dyskinesia who remained untreated with any VMAT2 inhibitor for 24 months, roughly 89% to 96% experienced at least a mild global impact and 60% to 74% experienced moderate-to-severe impact, while 55% to 69% reported stable or worsening severity with no evidence of spontaneous resolution.
Eisai's Subcutaneous Leqembi Wins Health Ministry Approval, Enabling At-Home Dosing
Eisai and U.S. pharmaceutical giant Biogen announced on the 16th that the subcutaneous formulation of their Alzheimer's disease treatment lecanemab, sold under the brand name Leqembi, has received manufacturing and marketing approval from the Ministry of Health, Labour and Welfare. The product, named Leqembi Subcutaneous Injection 250mg Pen, can be administered in about 15 seconds per pen, with two pens used per dose. Until now, patients needed intravenous infusions at a hospital once every two weeks, but the subcutaneous formulation allows once-weekly self-administration at home, though doctor visits will still be required for prescriptions and safety checks. Following deliberation and approval by the Central Social Insurance Medical Council, prescriptions are expected to begin between mid-November and mid-December. This is the third country to approve the subcutaneous version, after the United States and China.
Eli Lilly Hits $1 Trillion Market Cap as 24/7 Wall St. Sets $1,220 Price Target
Eli Lilly has crossed into trillion-dollar territory, trading at $1,123.98 with a market capitalization of $1.002 trillion, and 24/7 Wall St. rates the stock a buy with a 12-month price target of $1,220.42, implying 8.58% upside at 90% confidence. The company's second-quarter 2026 revenue reached $22.974 billion, up 47.67% year over year, with earnings per share of $8.38 beating consensus by 27.27%, and management raised full-year revenue guidance to $85 billion to $87 billion. Mounjaro alone posted $9.94 billion, up 91% year over year, while the incretin franchise generated roughly $14.87 billion of the quarter's revenue. The bull case targets $1,381.62, a 22.92% gain, driven by retatrutide's planned BLA submission in the first quarter of 2027, the oral GLP-1 Foundayo's expansion to 36,000 prescribers, and the Medicare GLP-1 Bridge Program opening access for 20 million eligible Americans at $50 per month. The bear case takes shares to $1,045.34, a 7% decline, citing realized prices that fell 13% in the second quarter, $2.78 billion in acquired IPR&D charges, and net insider selling. Lilly's forward price-to-earnings ratio of 24 compares with 14 for Novo Nordisk, which grew quarterly revenue just 2.1%, and 16 for Merck, whose quarterly earnings shrank 19.3% year over year.
Medical Costs Reach 49.2 Trillion Yen: Explaining the Increase in High-Cost Medical Care Ceilings and System Reforms
According to the latest data from the Ministry of Health, Labour and Welfare, Japan's total medical costs reached 49.2 trillion yen, an increase of about 1.3 trillion yen from the previous year. The growth rate was 2.6 percent. Although the number of days of medical treatment decreased, the rise in medical costs per day pushed up the total. Medical costs for those aged 75 and over were 20.3 trillion yen, accounting for 41.3 percent of the total, with per-person costs of 989,000 yen, about 3.8 times that of those under 75. From August 2026, the high-cost medical care system will be revised, raising the ceiling on out-of-pocket payments while introducing a new annual cap for long-term patients. Furthermore, under the medical insurance system reform law enacted in fiscal 2026, revisions to benefits for over-the-counter similar drugs, reflection of financial income of late-stage elderly, in-kind provision of childbirth costs, and expansion of insurance premium reductions for households raising children are planned.
Roche Gets FDA Clearance for Alzheimer's Blood Test
Roche Holding announced a collaboration with Treeline Biosciences to study combination immunotherapies for B-cell lymphomas, and received FDA clearance for its Elecsys pTau217 blood test, the first single biomarker assay to help rule in and rule out amyloid pathology in Alzheimer's disease. The test is intended to support earlier and more accessible Alzheimer's diagnostic assessments. Roche, a pharmaceuticals and diagnostics group with a CHF285.2 billion market cap, is expanding its oncology pipeline through partnerships and its diagnostics portfolio with neurology assays. The lymphoma partnership and the blood test clearance align with Roche's strategy of combining pipeline breadth and diagnostics depth, though the company faces competition from Novartis, Bristol Myers Squibb, Abbott, and Siemens Healthineers.
Eastspring: Healthcare Offers Defensive Growth Amid High Bond Yields
Eastspring Asset Management (Thailand) views the Healthcare sector as one of the most attractive investment opportunities amid a rotation of funds out of technology and AI stocks, as bond yields remain elevated. The firm notes that healthcare stocks have strong fundamentals and a trend of continued growth, or what is known as Defensive Growth, while institutions have been increasing their allocation to the sector. Between May 26 and August 25, 2026, the XLV Healthcare index rose 18.65%, while the Technology sector posted a negative return of 0.67%, and the MSCI World gained only 3.32%. The US 10-year yield stood at approximately 4.64%, up from 4.0% at the end of February, and could rise further on inflation concerns, which may continue to pressure technology stocks. Eastspring points out that Healthcare combines defensive characteristics, demand from an aging society, and growth, with S&P 500 Healthcare EPS expected to grow 21.3% in 2027, higher than the S&P 500's 11.94%. The BofA Global Fund Manager Survey for July 2026 found that Healthcare was the sector where fund managers increased their allocations the most. For interested investors, the ES-HEALTHCARE fund invests through the Janus Henderson Global Life Sciences Fund in life sciences stocks globally.
TUI Launches Longevity Portfolio from Tuna with 3 Ingredients, Tapping into Aging Trend
Thai Union Ingredients (TUI) has launched its Longevity portfolio at Vitafoods Asia 2026, presenting innovative solutions from three tuna-derived ingredients: DHA fish oil, collagen, and bio-calcium, which support brain function, skin health, and bone health, backed by scientific research. The company aims to generate at least $30 million in revenue from ThalaCol™ within five years and increase premium-grade omega-3 oil sales with an average annual growth rate of over 50% by 2030. This launch comes amid demographic shifts in Asia-Pacific, with UNFPA projecting that the population aged 60 and above will triple to 1.3 billion by 2050. Meanwhile, a 2025 McKinsey survey found that over 60% of consumers prioritize healthy aging. The three ingredients are developed from tuna by-products, including fish heads, skin, and bones, and are produced at facilities in Germany, Samut Sakhon, and Songkhla, supporting Thai Union's SeaChange® 2030 sustainability strategy.
Thai Union Ingredient Launches Longevity Portfolio from Tuna
Thai Union Ingredient (TUI), part of Thai Union Group Public Company Limited (TU), has launched its Longevity portfolio, an innovative range of ingredients derived from tuna, including DHA fish oil, collagen, and bio-calcium. These nutrients support brain function, skin health, and bone health, backed by scientific research and a tuna supply chain managed from source to end product. The launch comes as the Asia-Pacific region undergoes demographic shifts, with the United Nations Population Fund (UNFPA) projecting that the population aged 60 and above in the region will triple from 2010 to about 1.3 billion by 2050, accounting for one in four people in the region. Meanwhile, a 2025 McKinsey survey found that over 60% of consumers rank healthy aging as their top priority, and younger generations are increasingly proactive about their health. Ms. Leena Uabamrungjit, Senior Director of TU's Ingredient Business Group, said that most suppliers in the Longevity market specialize in specific areas rather than offering comprehensive solutions. The company has therefore developed a platform that brings together high-quality marine ingredients in one place, backed by a full supply chain, traceability systems, and research collaborations with leading universities. The three ingredients are: UniQ®OMEGA, a purified tuna oil rich in DHA that improves focus by 42% and working memory by 33%; ThalaCol™, a tuna collagen peptide that increases skin hydration by 68%, dermal density by 26%, and elasticity by 16%; and UniQ®BONE, a tuna bio-calcium that strengthens bone structure by 39%. These are developed from by-products of tuna processing—heads, skin, and bones—which most seafood processors cannot utilize. TU transforms them into high-value food ingredients at its tuna oil refinery in Germany, collagen production facility in Samut Sakhon, and calcium powder plant in Songkhla. The company aims to generate at least $30 million in revenue from ThalaCol™ within five years and to grow premium omega-3 oil sales at a compound annual growth rate (CAGR) of over 50% by 2030.
Thai Union Ingredient Launches Longevity Portfolio from Tuna
Thai Union Ingredient (TUI) has launched its Longevity portfolio at Vitafoods Asia 2026, presenting innovative ingredient solutions derived from tuna, including DHA fish oil, collagen, and bio-calcium, which support brain function, skin health, and bone health, backed by scientific research. The company aims to generate at least $30 million in revenue from ThalaCol™ within five years and increase premium-grade omega-3 oil sales with an average annual growth rate of over 50% by 2030. This launch comes amid demographic shifts in Asia-Pacific, with UNFPA projecting that the population aged 60 and above will triple to 1.3 billion by 2050, while a 2025 McKinsey survey found that over 60% of consumers prioritize healthy aging. The three ingredients are developed from tuna by-products, including fish heads, skin, and bones, processed at facilities in Germany, Samut Sakhon, and Songkhla.
200,000 Medicare users join Bridge obesity drug program
Medicare's Bridge program, which offers obesity drugs for a flat $50 per month, has enrolled at least 200,000 participants within its first 60 days, according to Jeremy Shane of the USC Leonard D. Schaeffer Institute. The program, launched July 1, 2026, and running through December 2027, targets Medicare Part D enrollees with conditions like high blood pressure or diabetes who otherwise lack weight-loss drug coverage. Experts say the rapid uptake signals significant pent-up demand, though Medicare originally estimated about 4 million recipients might qualify. An independent KFF analysis suggests 10% to 25% of eligible enrollees are using the program, costing Medicare between $1.3 billion and $3.3 billion, with costs potentially rising to $6.7 billion to $10 billion if 50% to 75% enroll. Healthcare analysts warn of an "affordability cliff" when the program ends in 2027, potentially driving patients to unregulated alternatives, while others highlight long-term benefits like reduced hospitalizations and cardiovascular events. Medicare recipients can check eligibility at Medicare.gov/glp1bridge or call 1-800-MEDICARE.
Taiwan Faces Demographic Crisis, Population Expected to Drop 48% to 12.15 Million by 2075
Bloomberg reports that Taiwan's population may decline to about 12.15 million by 2075, a drop of roughly 48% from 2026 levels, amid a continued decrease in births and young population, while the number of elderly rises significantly, posing long-term challenges to the labor market, economy, and defense capabilities. Estimates from Taiwan's National Development Council (NDC), based on household registration data, indicate that the working-age population will shrink by nearly two-thirds over the next 50 years. By 2075, the population aged 0-14 will be only 585,000, the working-age population (15-64) will be about 5.13 million, and those aged 65 and above will reach 6.43 million, meaning the elderly will outnumber the working-age population and account for more than half of the total population. These figures reflect risks after the population peaked at 23.6 million in 2019, and could also affect Taiwan's security, as the military still relies partly on conscription amid threats from China.
Medical costs hit record high of 49 trillion yen, rising for fifth straight year
The Ministry of Health, Labour and Welfare announced on the 28th that the estimated medical costs (preliminary figures) paid to medical institutions for treatment of illness and injury in fiscal 2025 increased by 2.6% from the previous year to 49.2 trillion yen. Due to an aging population and advances in medical care, costs have risen for five consecutive years, reaching a new record high. The growth rate had been shrinking for three consecutive years, but in fiscal 2025 it turned to expansion. A ministry official analyzed that "one factor is the increased use of expensive drugs such as anticancer agents."
Labcorp Unveils First FDA-Cleared Single Biomarker Alzheimer's Blood Test
Labcorp Holdings has introduced the Elecsys pTau-217 blood test, the first FDA-cleared single biomarker test for Alzheimer's disease, which expands access through primary and specialty care with a minimally invasive blood draw. The company also announced a long-term alliance with the National Association of Community Health Centers to support clinical leadership and community health outcomes across the largest US primary care network. These moves highlight how Alzheimer's diagnostics and broader healthcare delivery are changing quickly, and they align with Labcorp's strategy to use its scale and assay portfolio to drive routine test orders. The key proof point will be whether ordering volumes for pTau-217 and related tests build meaningfully within primary care and the NACHC network through 2027 without compressing pricing or margins.
FDA Clears Lilly-Roche Alzheimer's Blood Test; Healthcare ETFs to Watch
The U.S. Food and Drug Administration has granted clearance to the Elecsys pTau217 blood test, developed by Eli Lilly and Roche, making it the first and only FDA-cleared single-biomarker blood test for Alzheimer's that can both rule in and rule out amyloid-beta pathology using one validated clinical cutoff. With an estimated 7.4 million Americans aged 65 and older currently living with clinical Alzheimer's dementia, a figure projected to nearly double to 13.8 million by 2060, and national care costs expected to reach $409 billion this year, the approval is set to expand the eligible patient pool for disease-modifying therapies, potentially boosting the global Alzheimer's DMT market to $13.1 billion by 2030. Healthcare ETFs such as the State Street Health Care Select Sector SPDR ETF, iShares Global Healthcare ETF, VanEck Pharmaceutical ETF, and iShares Neuroscience and Healthcare ETF offer diversified exposure to these pharmaceutical giants and the growing Alzheimer's treatment market.
APCO Launches New Mylife100A Formula Targeting Longevity Market via BIM Advisor
APCO has launched a new formula of Mylife100A, targeting the longevity market and capitalizing on the trends of anti-aging and health restoration, while boosting sales through the BIM Advisor channel. The company expects the longevity market to continue growing as consumers shift toward preventive healthcare, particularly among the increasing elderly population. The company has therefore developed a new formula using innovative immunotherapy from mangosteen with synergistic effects, which has the potential to slow degeneration, reduce inflammation, and help lower risk factors for dementia such as Alzheimer's. Research findings are set to be published in an international academic journal within September. For the domestic market, the company uses BIM Advisor as the main channel to reach customers directly and is currently preparing to expand into international markets through a partnership with INFINITUM GLOBAL HEALTH (IGH), a partner from South Africa. Plans include an initial order of 1.5 million bottles of the mylife100 anti-aging formula with HIV management in the first year, and the partner will travel to Bangkok on September 7 to discuss operational plans, with a target to start exports within 2026. Meanwhile, for the second quarter of 2026, the company reported total revenue of 44.25 million baht and net profit of 11.06 million baht, while the first half of the year saw total revenue of 93.81 million baht and net profit of 28.95 million baht.
Global Atrial Fibrillation Market to Reach $38.7B by 2035
The global atrial fibrillation market is projected to grow from USD 21.4 billion in 2026 to USD 38.7 billion by 2035, at a compound annual growth rate of 6.8%, according to a new report from ResearchAndMarkets.com. The market expansion is driven by rising prevalence of the condition, an aging population, and increasing adoption of advanced diagnostic and treatment technologies. Antiarrhythmic agents account for about 55% of the therapy landscape, while monoclonal antibodies are emerging as an investigational approach. Nearly 60 catheter ablation and left atrial appendage closure devices are marketed or under development, with catheters representing approximately 40% of current treatment devices. North America is expected to remain the largest regional market, while Asia-Pacific is projected to see the fastest growth. Hospitals currently account for more than 80% of the end-user market. Key companies profiled include Abbott, Boston Scientific, Medtronic, Johnson & Johnson, Novartis, and Sanofi.
Health Ministry Requests Record 36.5 Trillion Yen Budget, Focusing on Drug Discovery and Advanced Medicine
The Ministry of Health, Labour and Welfare announced on the 26th its budget request for fiscal 2027, with a total general account of 36.58 trillion yen, up 4.4% from the initial budget for fiscal 2026, marking a record high. The increase is driven by rising social security costs due to an aging population. The ministry is prioritizing the strengthening of drug discovery and advanced medical care, and will begin supporting companies that develop innovative new drugs. Wage increases for care workers are listed as a "matter request" without specifying amounts, with the intention to finalize details during the budget formulation process at the end of the year.
Sunflower Pharmaceutical obtains drug registration certificate for glucosamine sulfate capsules
Sunflower Pharmaceutical Group's controlling subsidiary, Sunflower Pharmaceutical Group Hengshui Defeier Co., Ltd., recently received a drug registration certificate for glucosamine sulfate capsules issued by the National Medical Products Administration. The drug is registered as a Category 4 chemical medicine, classified as an over-the-counter product in Class A, with specifications of 0.25 grams calculated as glucosamine sulfate or 0.314 grams calculated as glucosamine sulfate sodium chloride, indicated for primary and secondary osteoarthritis. The company said the approval will further enrich its rheumatology and bone disease product pipeline in the elderly care segment. Through the implementation of its blockbuster single product and category cluster strategy, it will strengthen the company's competitive edge in chronic disease medications for the elderly and inject new momentum into performance growth. At the same time, the company cautioned that the launch and promotion of the drug are affected by multiple factors including national policies, market conditions, and corporate operating strategies, and that sales scale and performance outcomes remain uncertain.
Trump administration ends $9.8B Medicare Part D premium subsidy
The Trump administration has ended the Part D Premium Stabilization Demonstration, a $9.8 billion subsidy that kept Medicare drug premiums from rising for millions of Americans. The Centers for Medicare and Medicaid Services announced the rollback on July 28, 2026, reversing a Biden-era program created under the Inflation Reduction Act of 2022. The subsidy was designed to offset costs for insurers after the law capped out-of-pocket prescription costs at $2,000 a year, and the Government Accountability Office estimated premiums would have jumped from about $43 to $81 per month without it. CMS Administrator Mehmet Oz said most Medicare recipients will see premiums climb by less than $10, but KFF's Juliette Cubanski cautioned that some stand-alone drug plan enrollees could face larger increases in 2027. Beneficiaries will receive an Annual Notice of Change in the fall, and open enrollment runs from October 15 to December 7.
Vimut launches ViMUT Metabolic Health and Endocrine to address NCD trend
Vimut Hospital Holding has launched ViMUT Metabolic Health and Endocrine as a new growth area, focusing on personalised metabolic and endocrine care to tackle non-communicable diseases, or NCDs, which kill around 400,000 Thai people each year and cause economic losses of approximately 1.6 trillion baht per year, equivalent to 9.7 percent of GDP in 2019, according to World Health Organization data. The company has developed services into five clinical pathways: Metabolic Reset, Thyroid Wellness, Sarcopenic Obesity Care, Menopause and Weight, and Diabetes Care, under the Understand, Design, Measure, Partner care framework to assess risk, treat, and monitor health continuously. Dr Nipat Kulapkaew, Chief Executive Officer, said this approach shifts the conversation from asking about weight to caring for overall metabolic health, using medical data, nutrition, exercise, and health behaviour to plan care jointly between doctors and multidisciplinary professionals.
High-cost medical expense benefit cap to rise for all income brackets from August
From August, the out-of-pocket cap under Japan's high-cost medical expense benefit will be revised upward for all income brackets. The size of this increase has been held to roughly half of the 2025 proposal that was scrapped. The cap for people who qualify multiple times will remain at current levels, and for those with annual income below 2 million yen, the multiple-qualification cap will be revised from the current 44,400 yen to 34,500 yen from August 2027. An annual ceiling has also been newly introduced for long-term care patients. Meanwhile, from August 2027, people in income category 1, with annual income of roughly 16.5 million yen or more, will only become eligible for the high-cost medical expense benefit once their medical costs exceed 1.14 million yen. In other words, people in the top two income brackets will not receive the benefit even if their medical costs reach 1 million yen, and will have to pay 300,000 yen, or 30 percent, out of pocket.
UnitedHealth Group Raises Dividend and Exits Medicare Advantage Plans
UnitedHealth Group's board authorized a cash dividend of US$2.32 per share payable September 22, 2026, while outlining further exits from certain Medicare Advantage plans and updated margin expectations. The company plans to exit plans covering more than 600,000 members and expects a 1.1 million enrollment decline by 2026, targeting Medicare margins above 3%. Management also raised its 2026 adjusted EPS outlook, supported by lower medical costs. The company projects $498.6 billion revenue and $23.5 billion earnings by 2029, requiring 3.5% yearly revenue growth and a roughly $9.4 billion earnings increase from $14.1 billion today.
CVS Health Revamps Weight Management Program, Partners with Eli Lilly
CVS Health announced a revamp of its weight management program to improve access, affordability, and support for GLP-1 medications. The company is collaborating with Eli Lilly and Company to provide eligible Zepbound and Foundayo patients an additional access point at CVS Pharmacy through the CVS Health app, with transparent pricing including cash-pay options expected by early fourth quarter of 2026. CVS Pharmacy offers all FDA approved GLP-1s, and MinuteClinic digital weight loss visits have been lowered to $29, the most affordable option in the market, available 24/7 with no membership or recurring monthly fee. The program combines an online visit with a licensed clinician, same-day medication pickup at 9,000 local CVS Pharmacy locations, and in-person pharmacist support in one connected experience. CVS Pharmacy also participates in the Centers for Medicare & Medicaid Services Medicare GLP-1 Bridge program, which runs through December 31, 2027, offering eligible Medicare beneficiaries certain GLP-1 medications for $50 per month.
Life insurance association says pension and health premiums set to rise as people live longer
The Thai Life Assurance Association has said life insurance premiums are likely to decline over the long term because people are living longer, but pension and health insurance premiums are likely to increase. Mr. Sara Lamsam, vice president for marketing, said protection, term and whole life premiums need to be adjusted down, while pension premiums must be recalculated because companies have to pay pensions for longer. Health premiums are under pressure from medical inflation averaging 10 percent per year, as well as more deaths among younger cancer patients and higher-cost treatment technology. Mrs. Nusara Banyatpiyaphod, president of the Thai Life Assurance Association, said the co-payment measure has helped people be more careful about unnecessary hospital stays. The proportion of claimants subject to co-payment fell from 4 percent to no more than 1 percent, and it helped slow medical inflation in 2025 from a projected 15 percent down to 10.8 percent. The persistency rate for annual renewal policies stood at 84 percent, accounting for 72 percent of total premiums received, while the insurance penetration rate in the first quarter fell to 3.68 percent of GDP because of product restructuring under IFRS 17 and low interest rates. This has led companies to focus more on participating, unit-linked and protection products instead of savings products with high guaranteed returns. The ratio of policies to population remained stable at 38 to 39 percent.
TMAN first-half profit 212.2 million baht, advancing New S-Curve Longevity
T.Man Pharmaceutical Public Company Limited, or TMAN, reported first-half 2569 net profit of 212.2 million baht, down 7.2 percent from a year earlier, while total revenue came in at 1.2281 billion baht, up 8.2 percent, supported by distribution business for third-party brands growing 776 percent and contract manufacturing for external brands growing 631 percent. The board approved an interim dividend of 0.24 baht per share, with the XD date set for 26 August 2569 and payment on 8 September 2569. Chief Executive Officer Prapol Thanachotiphan said the company will move forward with building a New S-Curve in longevity healthcare, with plans to launch 7 to 10 core-brand products over the next six months, while expanding into overseas markets such as Korea and China, and expressed confidence that full-year performance will grow 10 to 15 percent as targeted.
Johnson & Johnson Advances Seltorexant and Expands Outpatient Cardiac Care
Johnson & Johnson is advancing its novel antidepressant Seltorexant into late-stage clinical development for major depressive disorder as a potential rapid-acting treatment option. The company also entered a multi-year partnership with ACCESS to expand adoption of advanced cardiac electrophysiology technologies in ambulatory surgery centers. Both moves align with Johnson & Johnson's focus on higher-growth therapeutic and medtech areas that are important for its long-term outlook.
Medical Insurance System Reform Bill Passed, Revising Burdens and Benefits in Five Key Points
The Act Partially Amending the Health Insurance Act and other laws, passed in May this year, will significantly overhaul the burden and benefit structure of the medical insurance system. The five key points of the reform are: introducing out-of-pocket costs for certain drugs that can be substituted with over-the-counter medications; establishing an annual cap for the high-cost medical expense system; reflecting financial income in the burden ratio determination for the latter-stage elderly medical care system; converting childbirth expenses to in-kind benefits with a fixed cash benefit; and expanding the 50% reduction in the per capita levy for children under National Health Insurance to cover those up to high school age. Of the total medical expenditure of 46.7 trillion yen, patient out-of-pocket costs amount to approximately 5.4 trillion yen, with the remainder covered by insurance premiums and public funds. The reform combines partial increases in burdens with enhanced coverage, and some provisions will take effect from April 1, 2027.
Eli Lilly raises 2026 revenue outlook to $85–$87 billion after 48% Q2 growth
Eli Lilly and Company raised its full-year 2026 revenue guidance to $85 billion to $87 billion and adjusted earnings-per-share guidance to $35.50 to $36.50 after reporting 48% year-over-year revenue growth in the second quarter. MOUNJARO and ZEPBOUND generated $14.9 billion in combined sales, contributing $6.3 billion of the year-over-year increase. The company also highlighted the July 1 launch of the Medicare GLP-1 Bridge Program, which expanded U.S. coverage for its obesity medicines by 35%, and said its oral medicine Foundayo increased its U.S. prescriber base to 36,000. Lilly reported positive Phase III results for retatrutide in obesity and plans to seek U.S. approval in the first quarter of 2027. The company also announced acquisitions in infectious disease, mental health, and neuroscience, and opened a new genetic medicine manufacturing facility in Lebanon, Indiana.
Niagen Bioscience launches Tru Niagen on Walmart.com alongside new epigenetic aging study
Niagen Bioscience Inc. has expanded distribution of its Tru Niagen healthy-aging NAD+ supplement onto Walmart.com, initially offering 300 mg bottles in 30- and 90-count formats, while a new peer-reviewed analysis in Aging Cell linked its nicotinamide riboside supplementation to reduced muscle epigenetic age acceleration. The Walmart.com launch places the product on a platform that generated US$27,100 million in U.S. e-commerce net sales and US$16,400 million in U.S. health and wellness net sales last quarter. The company reported slightly lower quarterly sales and net income year on year in early August 2026. Some analysts project revenue near US$225 million and earnings around US$41 million by 2029, though more cautious views see the clinic and injection channel as a niche opportunity.
Amazon offers Medicare patients GLP-1 weight-loss drugs for $50 a month
Amazon is widening its push into prescription healthcare by offering eligible Medicare patients GLP-1 weight-loss drugs for $50 per month through Amazon Pharmacy. The program joins the Medicare GLP-1 Bridge, a federal initiative launched July 1 that temporarily expands obesity-drug access for eligible Medicare Part D enrollees through December 31, 2027, with a fixed $50 monthly copay. Available treatments include Novo Nordisk's injectable and oral versions of Wegovy, Eli Lilly's Zepbound KwikPen, and Lilly's recently launched oral drug Foundayo. Free home delivery is available nationwide, while same-day service currently covers more than 3,100 U.S. cities and towns without requiring a Prime membership, with plans to extend to nearly 4,500 communities by year-end. The immediate financial contribution is likely modest for Amazon, which generated second-quarter revenue of $200.6 billion and operating income of $27.5 billion, but the program gives it a foothold in one of healthcare's fastest-growing drug categories.
Bristol-Myers Raises Full-Year Outlook as Cancer Drugs Drive Q2 Beat
Bristol-Myers Squibb lifted its full-year outlook after reporting better-than-expected second-quarter 2026 results driven by higher sales of its cancer therapies. The company posted approximately $13.0 billion in revenue, beating consensus by $1.23 billion, with its growth portfolio contributing $7.6 billion. Adjusted earnings per share rose about 40% year-over-year to $2.04, exceeding estimates by $0.44. Bristol-Myers now expects full-year revenue of about $49.0 billion to $50.0 billion and adjusted EPS of $6.75 to $7.00, up from prior guidance and ahead of consensus. In other healthcare news, Johnson & Johnson agreed to pay up to $5.5 billion to settle remaining talc lawsuits alleging its products caused ovarian cancer, conditioned on at least 95% participation by claimants. Curium is in advanced talks to acquire Lantheus Holdings for about $7 billion upfront, with an additional $12.50 per share in contingent value rights, potentially valuing the deal at $8 billion. Boston Scientific shares slipped after its full-year outlook trailed consensus, despite second-quarter revenue of $5.4 billion beating estimates. Most Medicare Part D enrollees will face higher premiums in 2027 after the Trump administration ended a subsidy program, with three out of four seeing increases. The S&P 500 Health Care Index Sector edged up 0.12% during the week.
CVS Health shares are trading about 6% below a fair value estimate of $111.92, according to a widely followed narrative. The stock last closed at $105.22, supported by a 90-day return of 28.18% and a one-year total shareholder return of 74.81%. The valuation story is anchored in rising healthcare demand from an aging population and growth in prescription services, though the stock’s price-to-earnings ratio of 45.8 times sits above a fair ratio of 40.6 times and well above the US healthcare industry average of 25.7 times. Analysts also flag risks from pharmacy reimbursement pressure and legal settlements that could weigh on future profitability.
CoBank report warns GLP-1 drugs and health trends pose long-term risk to U.S. sugar demand
A new CoBank report finds that while U.S. sugar deliveries remain strong and consumer intentions to cut sugar have not yet reduced consumption, longer-term risks are building from GLP-1 weight-loss medications and health-focused initiatives. J.P. Morgan estimates GLP-1 use could cut annual U.S. food and beverage spending by $30 billion by 2030 and $55 billion by 2034, with some projections showing grocery basket sizes declining up to 31% among active users. The report notes that 75% of consumers in 2025 reported trying to limit or avoid sugar, yet many also view low- or no-calorie sweeteners negatively, supporting demand for natural sweeteners over synthetic alternatives. USDA data through April shows increased sugar deliveries across wholesale grocers, beverage manufacturers, bakery and cereal producers, and confectionery companies, offsetting declines in other categories. CoBank food and beverage economist Billy Roberts said GLP-1 medications are poised to have the biggest impact on demand because they reduce overall consumption, and the potential impact could accelerate after 2031 when key semaglutide patents expire.
Asia Plus Securities says medical stocks will propel Thailand to become regional ATMP hub within four years
Asia Plus Securities says the Ministry of Public Health aims to push Thailand to become the regional hub for Advanced Therapy Medicinal Products, or ATMP Hub, within four years by upgrading ATMP industry standards covering cell production, storage, and transport, while requiring operators to meet GMP standards and obtain Cell Bank certification. The research team views this as directly positive for MEDEZE as the leader in Thailand's cell banking business, with over 50% market share and the country's first legally registered cell bank, reflecting readiness to expand into the ATMP business with leading medical institutions. If the ATMP Sandbox project makes concrete progress, it will be a key driver for the development of the anti-aging and regenerative medicine business, which has high growth potential. Currently, the company is awaiting registration of products for knee osteoarthritis and facial skin degeneration, and expects to start recognizing commercial revenue from 2027 onwards. Meanwhile, the growth of the ATMP industry provides structural support for the longevity business in the long term. BDMS stands out for expanding preventive health and anti-aging medicine services through WellEra and BDMS Wellness Clinic, covering anti-aging and regenerative medicine. Although the current revenue share is not high, it is a high-margin business that attracts high-purchasing-power customers. BH has a strength in VitalLife, which has been in the longevity business for over 20 years and is recognized by the premium medical tourism segment, thus also likely to benefit from the megatrend of anti-aging and health restoration medicine in the long term. The research team picks MEDEZE as the top stock for this theme due to the clearest growth potential in the ATMP business within the group, with a preliminary fair value of 8.00 baht based on historical P/E plus two standard deviations at 40.29 times, implying 22% upside, and recommends buying. BDMS and BH have opportunities to benefit from the long-term growth of the longevity and regenerative medicine business, with DCF-based fair values of 23.00 baht and 200.00 baht, respectively.
Sara Lamsam reveals MTL grew 9% in the first half, championing Life–Health–Wealth Span strategy for an ageing society
Mr Sara Lamsam, Chief Executive Officer of Muang Thai Life Assurance, disclosed first-half 2026 operating results. Total premiums received grew approximately 9%, with unit-linked products posting standout first-year premium growth of around 500%. The company is deploying a strategy to address the ageing society through the Life Span–Health Span–Wealth Span concept, which links longevity, health, and financial security together, so that Thai people can live longer with quality and have sufficient funds after retirement. Mr Sara noted that although people are living longer, the gap between healthy life years and average life expectancy can stretch to 11 years, while medical costs are rising due to medical inflation of about 10% per year. This makes Wealth Span — the period when one has enough money — a critical variable that is often overlooked. Muang Thai Life has therefore developed flexible products, such as allowing part of the life sum assured to be used for medical expenses upon reaching retirement age, and linking elderly care services to policies, to support a society where family structures are changing and the number of single people or elderly without caregivers is increasing. The company also places importance on building health literacy and developing T-shaped personnel to advise customers throughout their lives, with a capital adequacy ratio of approximately 490%, reflecting financial stability.
Trump administration ends Medicare Part D subsidy, raising 2027 premiums for most enrollees
A Trump administration decision to end a Medicare Part D subsidy program means that three out of four enrollees will see higher plan premiums in 2027. About 45% of enrollees will see an $11 to $20 monthly increase, while another 30% will pay $10 or under more per month, according to a report in The Wall Street Journal. An administration official told the newspaper that the subsidy provided an incentive for health insurers to boost rates as the federal government would foot the additional amount. The subsidy provided approximately $3.6 billion in support in 2026, according to the Government Accountability Office. The top Medicare Part D insurers include Centene, Humana, and UnitedHealth Group.
Congestive Heart Failure Market to Grow at 8% CAGR Through 2036, Reaching USD 9 Billion in 2025
The congestive heart failure market across the seven major markets was valued at USD 9 billion in 2025 and is projected to grow at a compound annual growth rate of 8% during the 2026 to 2036 forecast period, according to a new report from DelveInsight. The United States accounted for the largest share of the 7MM market in 2025, with nearly 7.4 million diagnosed prevalent cases out of approximately 21.1 million total diagnosed prevalent cases across the seven major markets. Growth is expected to be driven by the rising prevalence of cardiovascular diseases, an aging population, and the anticipated launch of emerging therapies such as Omecamtiv Mecarbil from Cytokinetics, Ziltivekimab from Novo Nordisk, CardiALLO Cell Therapy from BioCardia, and Umiposgene Parvec from Bayer. The report also highlights a robust clinical pipeline that includes candidates from AstraZeneca, Boehringer Ingelheim, Mesoblast, and AskBio, among others.
Cold-Chain Logistics for GLP-1 Drugs Emerges as Growth Driver for UPS and FedEx
United Parcel Service and FedEx are seeing a real business opportunity in shipping temperature-sensitive GLP-1 weight-loss and diabetes drugs, which require refrigerated transport. UPS posted its first-ever $3 billion healthcare revenue quarter earlier this year and announced a $48 million investment in 27 temperature-controlled facilities, targeting a biologics market expected to reach about $39.1 billion by 2033. FedEx launched a dedicated life sciences unit this month and reported nearly $10 billion in healthcare transportation revenue in its latest fiscal year, though its stock fell after core delivery margins slipped to 7.7% from 8.4% and investors grappled with the June 1 spinoff of its FedEx Freight unit. Hedge fund data shows a divergence, with 86 funds holding FedEx at the end of Q1 2026, up from 68, while UPS holdings fell to 59 funds from 67. Both companies are positioned to benefit from rising GLP-1 demand, but UPS's steadier overall business makes its healthcare story more visible to investors right now.
Medicare Advantage Plans Cut Grocery Cards and Dental Perks for 2026
Medicare Advantage plans are reducing supplemental benefits such as grocery cards and dental allowances for the 2026 plan year, even as many maintain $0 premiums. The overall MA market contracted by 9% to 3,373 individual plans, and 13% of individual MA-PD enrollees faced plan terminations, double the prior year's rate. While dental, vision, and hearing access remained broadly stable, fewer enrollees had plans offering over-the-counter benefits, meals, transportation, and in-home support. Insurers cite rising medical costs and payment pressure, with MedPAC estimating average rebates of nearly $2,400 per enrollee for individual plans in 2026. Beneficiaries whose plans are terminated generally receive guaranteed-issue rights for Medigap, but those in plans that cut benefits do not, and returning to Original Medicare outside the Medigap open-enrollment window can leave retirees with uncapped 20% coinsurance if insurers deny or price out coverage.
J.P. Morgan warns dwindling populations and fiscal deficits will drive interest rates higher
J.P. Morgan has warned that global interest rates are set to spike as the world runs out of the two forces that kept them low: fiscal discipline and demographic growth. In a note, the bank's research team highlighted that a global breakdown in fiscal discipline is occurring everywhere, with public debt reaching $100 trillion and elevated deficits pushing up borrowing costs. They also pointed to declining birth rates and aging populations in advanced economies, which will shrink the labor supply while demand for pensions and healthcare rises, ending the demographic dividend of the last 40 years. The U.S. fiscal deficit remains unsustainable, and neither political party is expected to address the Social Security shortfall before the 2032 cliff, which would require around $600 billion in new debt. J.P. Morgan views de-population as an underappreciated risk that will reduce savings and contribute to higher interest rates.